The effect of ezetimibe, administered alone or in combination with simvastatin, on lymphocyte cytokine release in patients with elevated cholesterol levels

Abstract.  Krysiak R, Zmuda W, Okopien B (Medical University of Silesia, Katowice; and and Electrotherapy and Angiology Centre, Oswiecim, Poland). The effect of ezetimibe, administered alone or in combination with simvastatin, on lymphocyte cytokine release in patients with elevated cholesterol levels. J Intern Med 2012; 271: 32–42.

[1]  C. Bode,et al.  Inflammatory mechanisms in atherosclerosis , 2013, Hämostaseologie.

[2]  B. Okopień,et al.  Effects of HMG-CoA Reductase Inhibitors on Coagulation and Fibrinolysis Processes , 2012, Drugs.

[3]  B. Okopień,et al.  The Effect of Simvastatin on Lymphocyte Secretory Function in Patients With Impaired Fasting Glucose , 2010, Journal of cardiovascular pharmacology.

[4]  S. Verma,et al.  Effects of Ezetimibe Add-on to Statin Therapy on Adipokine Production in Patients With Metabolic Syndrome and Stable Vascular Disease , 2010, Journal of cardiovascular pharmacology.

[5]  Sandra R. G. Ferreira,et al.  Synergistic effect of simvastatin and ezetimibe on lipid and pro-inflammatory profiles in pre-diabetic subjects , 2010, Diabetology & metabolic syndrome.

[6]  S. Yoshida,et al.  Ezetimibe ameliorates metabolic disorders and microalbuminuria in patients with hypercholesterolemia. , 2010, Journal of atherosclerosis and thrombosis.

[7]  G. Watts,et al.  Effect of Ezetimibe on Hepatic Fat, Inflammatory Markers, and Apolipoprotein B-100 Kinetics in Insulin-Resistant Obese Subjects on a Weight Loss Diet , 2010, Diabetes Care.

[8]  Yoshihisa Okamoto,et al.  Inflammation in atherosclerosis: transition from theory to practice. , 2010, Circulation journal : official journal of the Japanese Circulation Society.

[9]  J. Fildes,et al.  Ezetimibe and atorvastatin both immunoregulate CD4+ T cells from cardiac transplant recipients invitro. , 2009, Transplant immunology.

[10]  D. Gómez-Garre,et al.  Ezetimibe reduces plaque inflammation in a rabbit model of atherosclerosis and inhibits monocyte migration in addition to its lipid‐lowering effect , 2009, British journal of pharmacology.

[11]  K. Ley,et al.  Immune and inflammatory mechanisms of atherosclerosis (*). , 2009, Annual review of immunology.

[12]  T. Filippatos,et al.  Lipid-lowering drugs acting at the level of the gastrointestinal tract. , 2009, Current pharmaceutical design.

[13]  G. Moneta.  Effect of Statins Alone Versus Statins Plus Ezetimibe on Carotid Atherosclerosis in Type 2 Diabetes: The SANDS (Stop Atherosclerosis in Native Diabetics Study) Trial , 2009 .

[14]  M. Davidson.  Novel nonstatin strategies to lower low-density lipoprotein cholesterol , 2009, Current atherosclerosis reports.

[15]  P. Huang,et al.  Ezetimibe potently reduces vascular inflammation and arteriosclerosis in eNOS-deficient ApoE ko mice. , 2009, Atherosclerosis.

[16]  C. Weyand,et al.  T cells in arteritis and atherosclerosis , 2008, Current opinion in lipidology.

[17]  J. Chambers,et al.  Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis. , 2008, The New England journal of medicine.

[18]  A. Zwinderman,et al.  Simvastatin with or without ezetimibe in familial hypercholesterolemia. , 2008, The New England journal of medicine.

[19]  S. Feasson,et al.  MRC/BHF heart protection study of cholesterol lowering with simvastatin in 20536 high-risk individuals : a randomised placebo-controlled trial. , 2008 .

[20]  U. Lendeckel,et al.  DP IV/CD26, APN/CD13 and related enzymes as regulators of T cell immunity: implications for experimental encephalomyelitis and multiple sclerosis. , 2008, Frontiers in bioscience : a journal and virtual library.

[21]  C. Suárez,et al.  Effects of fluvastatin extended-release (80 mg) alone and in combination with ezetimibe (10 mg) on low-density lipoprotein cholesterol and inflammatory parameters in patients with primary hypercholesterolemia: a 12-week, multicenter, randomized, open-label, parallel-group study. , 2008, Clinical therapeutics.

[22]  S. Miura,et al.  Ezetimibe, a selective inhibitor of the transport of cholesterol. , 2008, Internal medicine.

[23]  P. Ridker.  Inflammatory biomarkers and risks of myocardial infarction, stroke, diabetes, and total mortality: implications for longevity. , 2007, Nutrition reviews.

[24]  J. Owczarek,et al.  Statins: a new insight into their mechanisms of action and consequent pleiotropic effects. , 2007, Pharmacological reports : PR.

[25]  D. Fuchs,et al.  Crucial Role of Interferon-γ and Stimulated Macrophages in Cardiovascular Disease , 2006 .

[26]  A. Tedgui,et al.  Cytokines in atherosclerosis: pathogenic and regulatory pathways. , 2006, Physiological reviews.

[27]  G. Schmitz,et al.  Ezetimib influences the expression of raft‐associated antigens in human monocytes† , 2006, Cytometry Part A.

[28]  D. Fuchs,et al.  Crucial role of interferon-gamma and stimulated macrophages in cardiovascular disease. , 2006, Current vascular pharmacology.

[29]  G. Schmitz,et al.  Aminopeptidase N (CD13) Is a Molecular Target of the Cholesterol Absorption Inhibitor Ezetimibe in the Enterocyte Brush Border Membrane* , 2005, Journal of Biological Chemistry.

[30]  K. Labuzek,et al.  The effect of statins and fibrates on interferon-gamma and interleukin-2 release in patients with primary type II dyslipidemia. , 2004, Atherosclerosis.

[31]  S. Lorkowski,et al.  Cholesterol absorption inhibitor Ezetimibe blocks uptake of oxidized LDL in human macrophages. , 2004, Biochemical and biophysical research communications.

[32]  L. Jonasson,et al.  Are early clinical effects of cholesterol lowering mediated through effects on inflammation? , 2002, Acta physiologica Scandinavica.

[33]  AndrewJ. S. Coats.  MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebocontrolled trial , 2002, The Lancet.

[34]  S. Yusuf.  MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20536 high-risk individuals: a randomised placebo-controlled trial. Commentary , 2002 .